Naoko Takebe MD PhD

Hematologic Oncology

Physician

31 Center Drive Bldg 31 Suite 3A44Bethesda, MD 20892
Phone+1 240-781-3398
Fax+1 240-541-4515

Dr. Takebe is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Takebe's full profile Already have an account?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1999
Sutter Health/California Pacific Medical CenterResidency, Internal Medicine, 1991 - 1994
OtherClass of 1988

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1992 - Present
NY State Medical License 1994 - 2028
MD State Medical License 1999 - 2027
OK State Medical License 2024 - 2027
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing the Safety of CB-5339 in Patients With Cancer Start of enrollment: 2020 Jun 18
WITHDRAWN
PHASE1
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel Start of enrollment: 2020 Aug 24
RECRUITING
PHASE2
A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas

Publications & Presentations

PubMed

KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer.
Ravi Thakur, Dezhen Wang, Tuo Hu, Chunbo He, Junzhang Zhao
Cancer Research. 2026-07-15
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subpro...
Shivaani Kummar, Zihe Song, Kim A Reiss, James M Ford, Li Chen
JCO Precision Oncology. 2026-06-01
Real-Time Breath Diagnostics: Linking Molecular Pathways, Measurement Technologies, and Clinical Translation.
Velmurugan Thavasi, Nirmal Choradia, Naoko Takebe, Neal Naito, Susan Yeyeodu
International Journal of Molecular Sciences. 2026-05-11

Lectures

Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptorâ€positive solid tumors including desmoid and gynecologic tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Grant Support

A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2019–2032
A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR2019–2032